No word yet from FDA on Northera; Deutsche comments

|By:, SA News Editor

With nervous Chelsea Therapeutics (CHTP -4%) still awaiting word from the FDA on Northera, Deutshce Bank's Robyn Karnauskas sees fair value for the stock in the $8-$9 range if the drug is approved and - more or less - $0 for the shares if declined.

Her team is modeling market share of 50% and peak sales of about $550M worldwide. Possibly higher market share and peak sales of about $780M could bring the stock up to the $12-$13 area.

Cash on the balance sheet in the case of non-approval is $21M, or $0.27 per share.